UniSuper Management’s Neurocrine Biosciences NBIX Stock Holding History

UniSuper Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$387K	Buy	2,294 +594	+35%	+$88.1K	﹤0.01%	602
2026 Q1	$224K	Hold	1,700	–	–	﹤0.01%	647
2025 Q4	$241K	Hold	1,700	–	–	﹤0.01%	648
2025 Q3	$239K	Hold	1,700	–	–	﹤0.01%	664
2025 Q2	$214K	Sell	1,700 -200	-11%	-$22.9K	﹤0.01%	675
2025 Q1	$210K	Hold	1,900	–	–	﹤0.01%	688
2024 Q4	$259K	Sell	1,900 -6,102	-76%	-$755K	﹤0.01%	666
2024 Q3	$922K	Buy	8,002 +1,070	+15%	+$147K	0.01%	576
2024 Q2	$954K	Buy	6,932 +5,532	+395%	+$759K	0.01%	595
2024 Q1	$193K	Buy	1,400 +700	+100%	+$95.6K	﹤0.01%	933
2023 Q4	$92.2K	Hold	700	–	–	﹤0.01%	658
2023 Q3	$78.8K	Hold	700	–	–	﹤0.01%	639
2023 Q2	$66K	Buy	+700	New	+$68.4K	﹤0.01%	668

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

UniSuper Management's NBIX Position: Q2 2026 in Review

UniSuper Management increased its Neurocrine Biosciences (NBIX) stake by 35% in Q2 2026, buying an estimated $88.1K and bringing the position to 2,294 shares worth $387K. The position accounts for ﹤0.01% of the portfolio, ranked #602.

UniSuper Management first reported a position in NBIX in Q2 2023 and has held it in 13 quarters since. The position peaked at $954K in Q2 2024. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

UniSuper Management held 2,294 shares of Neurocrine Biosciences worth $387K as of Q2 2026.
UniSuper Management bought 594 Neurocrine Biosciences shares in Q2 2026, an estimated $88.1K.
Neurocrine Biosciences made up ﹤0.01% of UniSuper Management's portfolio in Q2 2026, its #602 holding.
UniSuper Management first reported a position in Neurocrine Biosciences in Q2 2023 and has held it in 13 quarters since.
UniSuper Management's Neurocrine Biosciences position peaked at $954K in Q2 2024.
777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on UniSuper Management's 13F filing for Q2 2026, filed 14 Aug 2026.